Background. Vaccine failure with chronic hepatitis B virus (HBV) infection still develops in children after universal hepatitis B immunization. This study aimed to investigate the natural course of chronic HBV infection in children with vaccine failure and compare it with that of nonvaccinated children.
A universal hepatitis B immunization program of infants was launched in Taiwan in July 1984, and the current hepatitis B vaccination coverage rate in Taiwan is approximately 97% [1] [2] [3] . This pioneer immunoprophylaxis program provides a good example for the control of hepatitis B virus (HBV) infection in an endemic area. This program not only decreased the chronic HBV infection rate in vaccinated birth cohorts but also reduced the incidence of hepatocellular carcinoma (HCC) in children and adolescents. The hepatitis B surface antigen (HBsAg) seropositivity rate in the Taiwanese population was 10% in a nonvaccinated birth cohort, compared with <1% in a vaccinated birth cohort [4, 5] . Moreover, the incidence of HCC in children and adolescents decreased from 0.54 per 100 000 in the nonvaccinated birth cohort to 0.20 per 100 000 in the vaccinated cohort [4, 6] , born after initiation of the universal HBV immunization program [7] . However, the reduced incidence rate ratio by the universal hepatitis B vaccination program for HCC (68%-75%) is not as high as that for chronic HBV infection (90%) [6] .
The rates of HBV breakthrough infection in Asia, including Taiwan, Singapore, Korea, and China, in infants born to chronic HBV-infected mothers were reported to be 1%-11.8% [8, 9] . Maternal hepatitis B e antigen (HBeAg) status and HBV DNA level likely influence the rates. The overall breakthrough HBV infection rate in children born to HBsAg-positive mothers in Taiwan is 2.46%, compared with 9.26% for children born to HBeAg-positive, HBsAg-positive mothers, and 0.23% for those born to HBeAgnegative, HBsAg-positive mothers, respectively [1] .
We estimated previously that chronic HBV-infected children born after initiation of the universal HBV immunization program had a higher risk of developing HCC than did those born before the program (nonvaccinated children) (risk ratio, 2.3-4.5) [6] . However, the long-term impact of HBV immunoprophylaxis failure on the natural history of chronic HBV infection among vaccinated infants remains unclear. This study aimed to investigate the long-term natural course of chronic HBV infection in children in whom HBV vaccination failed, and to compare it with that of nonvaccinated children.
November 1992, a plasma-derived vaccine was administered at 0, 1, 2, and 12 months of age; after that, a recombinant vaccine was administered at 0, 1, and 6 months of age. Newborns of HBeAg-positive, HBsAg-carrier mothers receive hepatitis B immunoglobulin (HBIG) within 24 hours of birth, in addition to the HBV vaccine [2] .
Study Design and Subjects
Infants and children of a mainly community-based general population with chronic HBV infection were enrolled into this study, as follows: (1) 6 cross-sectional seroepidemiological surveys of HBV markers in children conducted in 1984, 1989, 1994, 1999, 2004, and 2009 ; (2) a prospective screening program for children of HBsAg-seropositive mothers; and (3) referral from school screening programs, other hospitals, or outpatient clinics.
Children with chronic HBV infection were prospectively followed up every 6 months, every 1-3 months if the alanine aminotransferase (ALT) level was elevated, or every 12 months if HBsAg became negative and hepatitis B surface antibody (anti-HBs) was positive. Biochemical and serologic markers-including ALT, aspartate aminotransferase, HBsAg, HBeAg, hepatitis B e antibody (anti-HBe), and α-fetoprotein-were routinely monitored, while HBV genotyping and viral load were performed as necessary. At the time of enrollment, all patients were <16 years of age, initially seropositive for HBeAg, and were followed up for at least 1 year. Those who received antiviral therapy during follow up were excluded. The vaccination records of the patients were reviewed to obtain information on hepatitis B vaccination and hepatitis B immunoglobulin. Maternal HBV serostatus was also checked. Children who had received 3 doses of hepatitis B vaccine before 7 months of age were defined as having complete HBV immunization and as the vaccine failure group in this study if they were HBsAg positive at enrollment. Those who were born before the start of the universal vaccination program, and therefore not vaccinated, were defined as the nonvaccinated (control) group. ALT levels above the upper limit of normal (30 IU/L), were defined as abnormal, according to our previous report. Chronic HBV-infected patients who had elevated ALT levels for >3 months were defined as having entered the inflammatory phase [10] . A special group of patients, monitored regularly starting from normal ALT status with no detectable elevation of serum ALT, or with elevation of ALT for <3 months before seroconversion, was defined as having a short or undetectable inflammatory phase. HBeAg seroconversion was defined as the end of the inflammatory phase-that is, loss of HBeAg and appearance of anti-HBe in at least 2 sequential blood samples.
Subgroup Analysis
Among the 436 patients enrolled in the study, 80 patients who received antiviral therapy during follow-up were excluded from the analysis of the natural clinical course of HBV infection (Figure 1 Those 80 patients included 59 nonvaccinated subjects and 21 vaccine failure. The baseline characteristics are shown in Supplementary  Table 1 . Thus, 356 HBeAg-positive subjects with chronic HBV infection who did not receive antiviral treatment during the study period were enrolled into this cohort study. To assess the difference in the inflammatory phase between nonvaccinated and vaccine failure subjects, the 356 subjects were divided into 2 groups. The first group comprised 242 subjects with initially normal ALT levels, who were in the immune-tolerance phase at the time of enrollment. The 114 subjects in the second group had abnormal ALT levels (ie, not in the immune-tolerance phase), at the time of enrollment. The data of the long-term followed subjects with normal initial ALT levels during the inflammatory phase were more comprehensive than that of the subjects with abnormal initial ALT levels. In other words, the condition of liver injury, inflammatory duration, and previous ALT level in subjects with abnormal initial ALT levels before enrollment were unknown. Moreover, subjects who did not receive HBV vaccination were inevitably older and had a longer follow-up duration compared with the vaccinated (vaccine failure) subjects. The latter were more likely to be enrolled at a younger age, as most of the cases originated from screening projects. To compare vaccine failure and nonvaccinated subjects over a comparable period, we therefore adjusted the follow-up period of the nonvaccinated group to be starting from the initial enrollment time and ending at a comparable duration of follow-up to that of the vaccine failure group.
Statistical Analysis
Statistical analysis was performed using Stata software version 12.0 (StataCorp, College Station, Texas), and survival graphs were created using the MedCalc software version 15.8 (MedCalc Software, Ostend, Belgium). Pearson χ 2 test and Fisher exact test were used to compare categorical variables, for example, sex, genotype, maternal HBsAg/HBeAg status, and cumulative HBeAg seroconversion rates. A 2-sample t test or Wilcoxon rank-sum test was used for comparisons of continuous variables. A value of P < .05 by 2-tailed t test was taken to indicate statistical significance. Univariate and multivariate Cox proportional hazards regression were applied to calculate the relative hazard ratios, 95% confidence intervals (CIs), and P values between the different factors. Bonferroni correction was used to adjust P values for multiple comparisons. Factors achieving P values < .0125 in univariate analysis were included in the multivariate Cox proportional hazards model. Kaplan-Meier survival analysis was applied to assess the timing of HBeAg seroconversion and logrank test was used to compare between the 2 groups.
RESULTS

Comparison Between the Nonvaccinated Group and Vaccine
Failure Group
The natural course of HBV infection in the 356 untreated children (199 males and 157 females) was investigated. Among these children, 105 received complete HBV immunization, while 251 did not. The median follow-up duration was 9.68 years (interquartile range, 4.62-18.83 years). There was no statistically significant difference in sex, initial enrollment age, follow-up duration, or final age between the 2 groups. Moreover, the proportion of cases being at the status of immune-tolerance phase between the 2 groups was comparable (P = .69) ( Table 1) .
The cumulative HBeAg seroconversion rate was significantly higher in the nonvaccinated group than in the vaccine failure group (77.7% vs 30.5%, P < .0001), during a comparable follow-up duration and age at the final follow-up (Table 2) . A total of 227 subjects, comprising 195 nonvaccinated and 32 vaccine failure subjects, achieved HBeAg seroconversion, irrespective of their initial ALT level. The median peak ALT level during the inflammatory phase in subjects who achieved HBeAg seroconversion did not differ between the 2 groups (P = .52). There was no difference in the duration of abnormal ALT levels during the inflammatory phase.
Genotype C HBV infection was more frequent in the vaccine failure than the nonvaccinated group (33.7% vs 13.4%, P < .0001) ( Table 1) . Moreover, the maternal HBsAg positivity rate was higher in the vaccine failure group than the nonvaccinated group (97.1% vs 66.4%, P < .0001) as well as the maternal HBeAg positivity rate (87.0% vs 64.1%, P = .0006).
The baseline HBsAg levels at the enrollment were checked in 248 of 356 enrolled children. The baseline HBsAg level was higher in the vaccine failure group than in the nonvaccinated group (P = .045).
Comparison of the Ending Time of the Immune-tolerance Phase and the
Starting Time of the Inflammatory Phase Between the Vaccine Failure and Nonvaccinated Groups in Children With Normal ALT Levels at Enrollment
A total of 242 cases with normal ALT levels were enrolled initially. The inflammatory phase of HBV natural course of these patients was more likely to be fully observed. Among them, 169 patients did not receive HBV vaccination, while vaccination failed in 73 subjects despite complete HBV immunization. There was no significant difference in sex, enrolled age, or age at the final follow-up between the 2 groups ( Table 3 ). The HBsAg seropositivity rate of mothers of chronic HBV-infected children was higher in the vaccine failure group than in the nonvaccinated group (98.6% vs 70.5%, P < .0001). Furthermore, a larger proportion of vaccine failure subjects were infected with genotype C than with genotype B plus B + C (P = .0004).
Among the above-mentioned 242 subjects, 131 underwent HBeAg seroconversion during the study period, of whom 120 were nonvaccinated and 11 were vaccine failure subjects. The inflammatory phase was thoroughly observed during the follow-up period in the 131 subjects with normal initial ALT levels who underwent HBeAg seroconversion. Both the median peak ALT level during the inflammatory phase and the duration of abnormal ALT levels showed no difference between the 2 groups.
We intended to compare the ending time point of immune-tolerance phase, that is, the initiating time point of inflammatory phase between the 2 groups. However, the inflammatory phase could not be well defined in 37 of the 131 subjects. There is no difference in basic characteristics between those 37 subjects and the other 94 subjects. In these 37 individuals, the serum ALT level was elevated for <3 months, or no elevation could be detected prior to HBeAg seroconversion. Determination of the timing of ending of the immune-tolerance phase was difficult in these 37 patients, who were thus excluded from this analysis, leaving 205 chronic HBV-infected subjects for further analysis. Among these 205 subjects, 135 subjects entered the inflammatory phase during the study period, including 106 nonvaccinated and 29 vaccine failure subjects. Under comparable age at the final follow-up, median age at the ending time of the immune-tolerance phase was 17.2 and 14.0 years of age, respectively (P = .06). In a Kaplan-Meier survival analysis, the results showed that the timing of the end of the immune-tolerance phase did not differ significantly between the 2 groups (Figure 2A) . We found by using Cox proportional analysis that the younger the age at the timing of ending of the immune-tolerance phase, the earlier the timing of HBeAg seroconversion was observed (P < .0001; Supplementary Table 2) .
Factors Affecting the HBeAg Seroconversion Rate
Among the 356 initially HBeAg seropositive cases, 227 (63.8%) achieved HBeAg seroconversion during the study period; these comprised 134 male and 93 female subjects (male to female ratio, 1.44). In a Kaplan-Meier survival analysis, HBeAg seroconversion was significantly delayed in vaccine failure subjects compared with nonvaccinated subjects (P = .0006) ( Figure 2B ). According to a life table analysis, the HBeAg seroconversion rate was higher (cumulative rate: 0.728) in the nonvaccinated group than in the vaccine failure group (cumulative rate: 0.432); The above-mentioned finding was reconfirmed by subgroup analysis. Among 255 maternal HBsAg-positive chronic HBVinfected children, the cumulative HBeAg seroconversion rate was lower in the vaccine failure group (P = .009). Among 235 nonvaccinated subjects, 156 of their mother's HBsAg were positive and 79 negative. The cumulative HBeAg seroconversion was lower in maternal HBsAg-positive nonvaccinated group (P = .02) ( Supplementary Figures 1 and 2) .
Two other potential factors that might delay HBeAg seroconversion were the age of ending of immune-tolerance phase (HR, 0.76; P < .0001) and baseline HBsAg level at enrollment (HR, 0.56; P < .0001). However, the data of these 2 factors were not available in some enrolled cases, which might lead to decrease in the power and make previous significant factors less significant in multivariate analysis (Supplementary Table 2 , multivariate model 2).
DISCUSSION
Taiwan launched the world's first universal HBV vaccination program for >30 years. This has enabled investigation of the long-term impact of HBV vaccine failure on the natural history of chronic HBV infection.
HBeAg seroconversion is indicative of lower viral replication and reduced hepatitis activity in chronic HBV-infected patients [11] . Furthermore, it is also an important goal of current antiviral treatment [10] . Our study revealed a novel finding: that during the natural course of chronic HBV infection, vaccine failure subjects had a lower cumulative HBeAg seroconversion rate than that of nonvaccinated subjects; the difference was statistically significant after puberty according to a life table analysis. The average annual HBeAg seroconversion rate was lower in the vaccine failure group (1.73%) than in the nonvaccinated group (2.91%). Moreover, vaccine failure subjects demonstrated a prolonged period of HBeAg seropositivity and a lower HBeAg seroconversion rate. Subjects in whom vaccination failed might have been infected with mutant HBV or simultaneously with wild-type and mutant HBV [12] . Indeed, our previous study revealed that HBV genotype C has a higher genome mutation rate [13] . Moreover, as shown in this study, the proportion of HBV genotype C infection has increased in the postvaccination era.
The delayed HBeAg seroconversion in vaccine failure subjects might be a result of infection with HBV genotype C, or a prolonged immune tolerance to HBV after perinatal or intrauterine infection of HBV by highly infectious mothers despite HBV immunization. In our multivariate analysis, HBV vaccine failure, genotype C infection, and maternal HBsAg positivity were significantly associated with delayed HBeAg seroconversion. Delayed HBeAg seroconversion may prolong HBV replication and liver injury, leading to a higher risk of liver cirrhosis and HCC [14] . The delayed HBeAg e We focused on subjects who completed HBeAg seroconversion (the inflammatory phase) in the nonvaccinated and vaccine failure groups.
seroconversion in vaccine failure group should be highly emphasized and monitored. How to properly intervene with chronic HBV-infected children in whom vaccination fails is an important issue to be further investigated to prevent delayed seroconversion and to reduce the risk of complications such as severe liver injuries and/or HCC. The universal HBV vaccination program has been successful in preventing horizontal transmission of HBV. Mother-toinfant transmission plays an important role in breakthrough chronic HBV infection [15] . Approximately 97% of HCC cases among children born after the launch of the vaccination program were HBV related, caused mainly by mother-to-infant transmission of HBV due to vaccine failure and/or not receiving HBIG at birth [3, 16] . The current 3-dose HBV vaccination and HBIG immunoprophylaxis policy cannot fully eradicate intrauterine or perinatal HBV infection. High maternal HBV viral load, emergence of HBV surface antigen mutants, and nonresponsiveness to HBV vaccination are the principal causes of immunoprophylaxis failure [8, 17, 18] .
The proportion of children with chronic HBV infection born to mothers seropositive for HBsAg increased significantly from 66.4% to 97.1% in our cohort in the postimmunization era [2, 16] . Following introduction of an HBV immunization program in Japan, the rate of mother-to-infant transmission also increased from 62% during 1991-1995 to 86% during 2006-2010 [15] . In both univariate and multivariate analyses in our study, maternal HBsAg seropositivity (or mother-to-infant transmission) confirms the delay of HBeAg seroconversion of their offspring. Children of HBsAg-positive mothers have a lower annual HBeAg seroconversion rate than those of HBsAgnegative mothers [19] [20] [21] . In our previous study, maternal HBeAg was associated with delayed HBeAg seroconversion in offspring with chronic HBV infection [22] . However, the impact of maternal HBeAg was not observed in our cohort study. This After excluding 114 subjects with initial abnormal alanine aminotransferase levels and 37 subjects with a short or undetectable inflammatory phase, 136 nonvaccinated and 69 vaccine failure subjects with chronic HBV infection were subgrouped and subjected to a survival analysis. There was no difference in the timing of the end of the immune-tolerance phase between the subgroups. B, Timing of hepatitis B e antigen (HBeAg) seroconversion. Three hundred fifty-six subjects with chronic HBV infection, comprising 251 nonvaccinated and 105 vaccine failure subjects, were included in this analysis. HBeAg seroconversion occurred significantly later in the vaccine failure group than in the nonvaccinated group.
might result from the available status of maternal HBeAg in only 52.2% of the current study cases. Thus, the importance of HBeAg might not be disclosed fully. The maternal HBsAg seropositivity associated with high HBV viral load is the major factor in mother-to-infant transmission [23] [24] [25] and immunoprophylaxis failure, which lead to delayed HBeAg seroconversion in offspring and possibly a poor outcome. At least 10 HBV genotypes and several subtypes have been identified [26] . The HBV genotype distribution differs geographically. In Taiwan, genotype B accounted for >80% of chronic HBV infections prior to the immunization era [27] ; the remaining strains were of genotype C. In our cohort study, the prevalence of genotype C infection increased following initiation of universal HBV immunization, and HBeAg seroconversion was delayed in subjects infected with HBV genotype C. In the post-immunization era, the proportion of HBV genotype C infection cases among chronic HBV carriers was higher than that prior to institution of the universal vaccination program (33.7% vs 13.4%, P < .0001). The proportion of genotype C infection in the mothers of chronic HBV-infected subjects with vaccine failure was similar to that of nonvaccinated chronic HBV-infected subjects. This indirectly excludes the possibility that the shift in HBV genotype distribution is a result of the maternal HBV genotype distribution. Thus, immunoprophylaxis failure (or breakthrough HBV infection) is more likely in children born to mothers infected with genotype C than genotype B HBV. Compared with genotype B, infection with HBV genotype C has a relatively poor outcome, including a higher rate of HBeAg positivity, delayed HBeAg seroconversion, a lower rate of HBsAg seroclearance, a poorer response to interferon therapy, a higher HBV load, and higher risks of cirrhosis and HCC [26, 28] .
Although immunoprophylaxis failure delayed HBeAg seroconversion significantly, its influence during the immune-tolerance phase of chronic HBV infection remains to be elucidated. Study on the factors that affect the ending time of the immune-tolerance phase is still lacking in the literature. Most follow-up studies were initiated at the stage of abnormal ALT levels, which lost the power to answer this question. In our current prospective cohort study, 205 patients with normal initial ALT levels were subgrouped for further analysis of the ending time of the immune-tolerance phase. No difference in the age at the ending time of the immune-tolerance phase (or beginning of the inflammatory phase) was found between the nonvaccinated and vaccine failure subjects. Further studies involving a larger number of subjects and longer follow-up duration are required to identify the factors that lead to the breakthrough of the immune-tolerance phase and the advance of the inflammatory phase. This will facilitate the development of novel therapies for individuals with chronic HBV infection.
The limitations of this long-term longitudinal prospective analysis are as follows. The timing of subject enrollment was after 1980-that is, both before and after launch of the HBV vaccination program in Taiwan. The subjects in the vaccine failure group were born after July 1984. They were more likely to be enrolled at a younger age. Subjects who did not receive HBV vaccination were inevitably older and had a longer follow-up duration compared with the vaccinated (vaccine failure) subjects. For this reason, the initial and final follow-up time of the nonvaccinated cohort was adjusted only up to a comparable time to the vaccine failure group.
In conclusion, when comparing vaccine failure children with nonvaccinated children with chronic HBV infection, vaccine failure children are prone to maintain longer duration of the HBeAg seropositivity during long-term follow-up. They are more likely to have HBV genotype C infection and infected by maternal transmission. Timely proper intervention for HBeAgseropositive vaccine failure HBV carrier children may be needed to prevent delayed HBeAg seroconversion and higher risk for complications.
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